Patents by Inventor Christopher Robert Bebbington

Christopher Robert Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5827739
    Abstract: Recombinant DNA sequences which encode the complete amino acid sequence of a glutamine synthetase, vectors containing such sequences and methods for their use, in particular as dominant selectable markers, for use in co-amplification of non-selected genes and in transforming host cell lines to glutamine independence.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 27, 1998
    Assignees: Celltech Therapeutics Limited, The University Court of the University of Glasgow
    Inventors: Richard Harris Wilson, Christopher Robert Bebbington
  • Patent number: 5770359
    Abstract: Recombinant DNA sequences which encode the complete amino acid sequence of a glutamine synthetase, vectors containing such sequences, and methods for their use, in particular as dominant selectable markers, for use in co-amplification of non-selected genes and in transforming host cell lines to glutamine independence are disclosed.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: June 23, 1998
    Assignees: Celltech Therapeutics Limited, The University Court of the University of Glasgow
    Inventors: Richard Harris Wilson, Christopher Robert Bebbington
  • Patent number: 5747308
    Abstract: There is described a method for obtaining a eukaryotic cell containing in its DNA multiple copies of a GS gene, comprising: transforming a eukaryotic glutamine auxotroph with a GS gene; selecting transformant cells containing the GS gene; and culturing the selected transformant cells in a medium which lacks glutamine or in which the amount of glutamine is progressively depleted, the GS gene being of a character such that, or the conditions employed during the culturing step being such that, the GS gene is so weakly transcribed that the cells in which the GS gene has been amplified are selected.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: May 5, 1998
    Assignee: Celltech Therapeutics Limited
    Inventors: Christopher Robert Bebbington, Geoffrey Thomas Yarranton
  • Patent number: 5658759
    Abstract: The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described. Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: August 19, 1997
    Assignee: Celltech Limited
    Inventor: Christopher Robert Bebbington